PIK-293 is primarily utilized in research settings as a potent and selective inhibitor of the PI3K (phosphoinositide 3-kinase) pathway, specifically targeting the p110α isoform. Its application is significant in the study of cancer biology, as the PI3K pathway is frequently dysregulated in various cancers, contributing to tumor growth, survival, and metastasis. By inhibiting this pathway, PIK-293 helps researchers understand the role of PI3K signaling in cancer progression and evaluate its potential as a therapeutic target. Additionally, it is employed in preclinical studies to assess the efficacy of PI3K inhibition in combination with other anticancer therapies, aiding in the development of novel treatment strategies. Beyond oncology, PIK-293 is also used in studies exploring the role of PI3K in other diseases, such as metabolic disorders and immune system dysfunctions, providing insights into its broader biological implications.